Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

European approval recommended for Levemir as add-on to Victoza

Sep. 27, 2011

Phase II/III data on antidiabetic efficacy of insulin degludec and insulin degludec/insulin aspart

Sep. 27, 2011

EMA begins review of orlistat-containing antiobesity medicines

Sep. 26, 2011

New 11-beta-HSD1 inhibitor shows promise to treat type 2 diabetes and complications

Sep. 26, 2011

EMA committee recommends extending approval of Levemir

Sep. 23, 2011

BMS and Ambrx establish partnership for biologics

Sep. 23, 2011

New Mnk inhibitors patented by Boehringer Ingelheim

Sep. 23, 2011

Korean university synthesizes new PPAR-beta/delta ligands

Sep. 23, 2011

GetGoal-F1 results add to phase III data on lixisenatide in type 2 diabetes

Sep. 23, 2011

Japanese MHLW adds fenofibrate tablets to NHI price list

Sep. 23, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...